Press release content from PR Newswire. The AP news staff was not involved in its creation.

CardieX Subsidiary ATCOR Partners with Invaryant to Enable Clinical Trials with Advanced New AI Medical Technology

PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.
January 3, 2023 GMT

CardieX’s ATCOR subsidiary and Invaryant will work cohesively to conduct trials and improve patient outcomes

IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ -- CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes, today announced a partnership between its ATCOR subsidiary and Invaryant, a data-driven health technology company that empowers individuals with precision AI to improve quality, equity and safety, and provides comprehensive, integrated, high quality data to accelerate research and innovation.

The new partnership will allow ATCOR and Invaryant to jointly conduct clinical trials and research on maternal health and cardiovascular disease.

In an effort to improve patient outcomes across clinical trials and healthcare research, the partnership will primarily focus on the integration of digital vascular biomarkers using ATCOR’s SphygmoCor® technology into Invaryant’s health platform, thereby enabling a more patient-focused monitoring of hypertensive disorders that signal risk factors across multiple therapeutic areas (including maternal health and cardiovascular diseases, the leading cause of global deaths and disability according to the CDC). Together, ATCOR and Invaryant are redefining patient-centric monitoring by integrating a collection of digital vascular biomarkers which will seamlessly correlate with imaging and molecular biomarkers in order to better understand and personalize a patient’s vascular health.

Clinical trials and healthcare research has shifted to a focus on prevention through monitoring the patient and evaluating clinically relevant digital biomarkers that signal a patient’s progress and risk through a treatment program. The continuous monitoring of digital vascular biomarkers enhances therapeutic efficacy at the patient level by individualizing care and/or interventions that can reduce adverse events. The benefits are a decreased overall time frame and lower costs for clinical trials.

The “Pulse”, a new device from CardieX subsidiary CONNEQT, will provide advanced arterial health metrics to users from the comfort of their own home. Pulse was developed as a primary decentralized clinical trial device to enhance patient monitoring. Pulse will integrate with Invaryant’s health platform for a holistic perspective of patient care with EMR data, imaging data, molecular data, and other relevant clinical data. Invaryant’s Inara – a personable AI bot designed to support patients and increase patient engagement – offers over 150 language preferences to support global clinical trials in nearly every region of the world.

“CardieX is advancing patient-centric clinical trials and healthcare research by collecting personalized digital vascular biomarker data to help us understand the most challenging aspects of human health and disease. I am thrilled to have Invaryant as our partner. Together, our combined technologies will create a global real world data platform integrating vascular health monitoring data to fundamentally understand the cause of disease,” said Toni R. Hofhine, President of CardieX subsidiary ATCOR Medical.

“It’s exciting to see patient-driven technologies expand and enhance decentralized clinical trial outcomes. The ATCOR and Invaryant partnership will integrate the best in personalized vascular biometric monitoring with Inara’s advanced AI and machine learning (ML) to help educate patients about their vascular health and improve patient reported outcomes. I’m excited to leverage our combined technologies for the best patient experience and access to the most meaningful data”, said Craig Cooper, Group CEO of the CardieX companies.

“Our passion at Invaryant is to provide a platform that ensures everyone has access to the right medical data at the right time,” said Ramon Dempers, CEO of Invaryant. “There is no doubt in my mind that the data from CardieX will save lives and we are proud to be a part of integrating that data into our platform for both clinical and research purposes.”

The Pulse device will be available for healthcare research and clinical trials in early 2023.

For more information, visit,, and

About CardieX:

CardieX is a global health technology company. Its ATCOR subsidiary is a world leader in medical devices for hypertension, cardiovascular disease, and other vascular health disorders based on the Company’s “gold standard” SphygmoCor® central blood pressure technology. CardieX’s CONNEQT subsidiary develops and markets medical devices, digital solutions, and wearables for home health, primary clinician, and other healthcare channels. CardieX is listed on the Australian Stock Exchange (ASX:CDX).

About Invaryant:

Founded upon the belief that all people have a right to equitable care, Invaryant offers the first end-to-end solution built from its foundation to address the massive information and communication gaps plaguing healthcare and clinical research. Invaryant has woven patented security and interoperability technologies with first-of-its-kind AI, Inara, to intelligently support patients and their healthcare providers, making Invaryant the ideal platform for person-centric healthcare and clinical research.

View original content:

SOURCE CardieX Limited